Similar articles

• Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.

  Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, Orsulic S. Liu Z, et al. Gynecol Oncol. 2015 Dec;139(3):394-400. doi: 10.1016/j.ygyno.2015.08.026. Epub 2015 Sep 6. Gynecol Oncol. 2015. PMID: 26348314 Free PMC article.
• Role of laparoscopy in predicting surgical outcomes in patients undergoing interval cytoreduction surgery for advanced ovarian carcinoma: A prospective validation study.

  Tomar TS, Nair RP, Sambasivan S, Krishna KMJ, Mathew A, Ahmed IM. Tomar TS, et al. Indian J Cancer. 2017 Jul-Sep;54(3):550-555. doi: 10.4103/ijc.IJC_306_17. Indian J Cancer. 2017. PMID: 29798957
• The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.

  Chi DS, Venkatraman ES, Masson V, Hoskins WJ. Chi DS, et al. Gynecol Oncol. 2000 May;77(2):227-31. doi: 10.1006/gyno.2000.5749. Gynecol Oncol. 2000. PMID: 10785469
• Role of aggressive surgical cytoreduction in advanced ovarian cancer.

  Chang SJ, Bristow RE, Chi DS, Cliby WA. Chang SJ, et al. J Gynecol Oncol. 2015 Oct;26(4):336-42. doi: 10.3802/jgo.2015.26.4.336. Epub 2015 Jul 17. J Gynecol Oncol. 2015. PMID: 26197773 Free PMC article. Review.
• Epithelial ovarian carcinoma.

  Kristensen GB, Tropé C. Kristensen GB, et al. Lancet. 1997 Jan 11;349(9045):113-7. doi: 10.1016/S0140-6736(96)06071-0. Lancet. 1997. PMID: 8996432 Review. No abstract available.